CorMedix
CRMD
86 hedge funds and large institutions have $76.1M invested in CorMedix in 2023 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 13 closing their positions.
169% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 13
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
92% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 12
70% more capital invested
Capital invested by funds: $44.7M → $76.1M (+$31.4M)
32% more funds holding
Funds holding: 65 → 86 (+21)
16.22% more ownership
Funds ownership: 26.06% → 42.28% (+16%)
61% less call options, than puts
Call options by funds: $615K | Put options by funds: $1.59M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$6.12M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$5.47M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.95M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$752K |
| 2 |
Jane Street
New York
|
-$474K |
| 3 |
D.E. Shaw & Co
New York
|
-$371K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$361K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$360K |
CRMD Hedge Fund Activity: Q2 2023 in Review
86 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q2 2023, worth a combined $76.1M — up 70% from $44.7M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CRMD positions and 13 closed out — a net gain of 22 holders — while 23 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $10.3M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $752K sold.
- 86 institutional investors held CorMedix (CRMD) as of Q2 2023, up from 65 in Q1 2023.
- Funds reported $76.1M of CorMedix stock for Q2 2023, up 70% quarter-over-quarter.
- 35 funds opened new CorMedix positions in Q2 2023 and 13 closed out, a net change of +22 holders.
- The largest CorMedix buyer in Q2 2023 was BlackRock, an estimated $10.3M added.
- The largest CorMedix seller in Q2 2023 was Renaissance Technologies, an estimated $752K sold.
Based on aggregated 13F filings for Q2 2023.